Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Australia

Australia Articles

Industry

BMI Core View: Uptake of generic drugs following patent expiry will become swifter. This trend will reduce costs for governments, out-of-pocket payers and insurance companies, which... 2010-07-20


Industry

Reinforcing its aim to boost its presence in the fast-growing global generic medicines market, South African drugmaker Aspen Pharmacare has bid US$750mn for debt-laden Australian drugmaker... 2010-05-25


Industry

BMI Core View: Uptake of generic drugs following patent expiry will become swifter. This trend will reduce costs for governments, out-of-pocket payers and insurance companies, which... 2010-05-06


More ARTICLES

Industry

Australia's AUD10.07bn (US$7.93bn) pharmaceutical market is the fourth largest in Asia Pacific, behind South Korea (US$10.45bn) and ahead of Taiwan (US$3.80bn). However, at US$359... 2010-04-08


Industry

Australia is an ideal location for clinical trials. The country has a developed healthcare system, a transparent regulatory system that meets international standards, an established... 2010-04-06


Industry

It is BMI's view that the almost 50% decrease in Australian firm Sigma Pharmaceuticals's share price can be attributed to over-optimistic forecasting. Following its US$2.2bn merger... 2010-03-31


Industry

Asia Pacific's respect for intellectual property rights with regard to medicine has improved marginally over the past 12 months, according to the Pharmaceutical Research and Manufacturers... 2010-03-09


Industry

BMI's Pharmaceuticals & Healthcare service's newest long-term core view is that many developed countries will overhaul their healthcare systems. Current approaches to the delivery... 2010-03-08